Piwi-interacting RNA-823 promotes cell growth and chemoresistance by stimulating the TGF-β1-mediated AKT/ERK pathway in multiple myeloma
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115405 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Wei Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Zhabei Central Hospital of Shanghai Jing'an District, Shanghai 200070, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Transforming Growth Factor beta1, RNA, Small Interfering. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Piwi-interacting RNA (piRNA)-823 contributes to oncogenesis and tumor progression through multiple genes and pathways in several solid cancers and hematologic malignancies. Hence, the current study aimed to further explore the effects of piRNA-823 on cell growth and chemoresistance in multiple myeloma (MM) and the underlying molecular mechanism involved. METHODS: Bone marrow plasma piRNA-823 expression was detected in 15 newly diagnosed MM (NDMM) patients, 15 relapse/refractory MM (RRMM) patients and 5 iron deficiency anemia patients as controls. The control mimic, piRNA-823 mimic, control inhibitor and piRNA-823 inhibitor were transfected; then, the control inhibitor and piRNA-823 inhibitor were transfected alone or in combination with transforming growth factor β1 (TGF-β1) into U266 or RPMI-8226 cells. piRNA-823, TGF-β1, cleaved caspase 3, Bcl-2, protein kinase (AKT), pAKT, extracellular signal regulated kinase (ERK), pERK, cell proliferation, apoptosis and chemoresistance were evaluated. RESULTS: piRNA-823 expression was greater in NDMM patients and RRMM patients than in controls and was also greater in RRMM patients than in NDMM patients (all P < 0.01). In U266 and RPMI-8226 cells, piRNA-823 knockdown decreased proliferation and Bcl-2 expression but increased apoptosis, cleaved caspase-3 expression, and chemoresistance to bortezomib and lenalidomide (all P < 0.05). Moreover, piRNA-823 overexpression had opposite and weaker effects on these functions. piRNA-823 positively regulated the TGF-β1-mediated AKT/ERK pathway (all P < 0.05). Notably, TGF-β1 weakened the effects of piRNA-823 knockdown on the AKT/ERK pathway, cell proliferation, apoptosis, and apoptotic markers and, importantly, the chemoresistance to bortezomib and lenalidomide (all P < 0.05). CONCLUSION: piRNA-823 promotes cell growth and chemoresistance by stimulating the TGF-β1-mediated AKT/ERK pathway in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Zhabei Central Hospital of Shanghai Jing'an District, Shanghai 200070, China.
- Department of Hematology, Wuhan Puren Hospital, Wuhan 430081, China.
- Department of Hematology and Oncology, Zhabei Central Hospital of Shanghai Jing'an District, Shanghai 200070, China. Electronic address: zhoufan_sh@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wei, W., Wang, D., Zhou, N., Chen, H., Yu, W., Wu, L., Peng, R., Shi, H., & Zhou, F. (2025). Piwi-interacting RNA-823 promotes cell growth and chemoresistance by stimulating the TGF-β1-mediated AKT/ERK pathway in multiple myeloma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115405
Vancouver
Wei W, Wang D, Zhou N, Chen H, Yu W, Wu L, et al. Piwi-interacting RNA-823 promotes cell growth and chemoresistance by stimulating the TGF-β1-mediated AKT/ERK pathway in multiple myeloma. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115405
BibTeX
@article{Wei2025,
author = {Wei, Wei and Wang, Dongjiao and Zhou, Nian and Chen, Haimin and Yu, Wenjun and Wu, Lixia and Peng, Rong and Shi, Haotian and Zhou, Fan},
title = {Piwi-interacting RNA-823 promotes cell growth and chemoresistance by stimulating the TGF-β1-mediated AKT/ERK pathway in multiple myeloma},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115405}
}
EUVIMED